

1. Company details

Name of entity:	EZZ Life Science Holdings Limited
ABN:	83 608 363 604
Reporting period:	For the year ended 30 June 2025
Previous period:	For the year ended 30 June 2024

2. Results for announcement to the market

			\$
Revenues from ordinary activities	up	0.65% to	66,873,691.00
Profit from ordinary activities after tax attributable to the owners of EZZ Life Science Holdings Limited	down	3.36% to	6,730,441.00
Profit for the year attributable to the owners of EZZ Life Science Holdings Limited	down	3.36% to	6,730,441.00

Dividends

	Amount per security Cents	Franked amount per security Cents
Final dividend paid on 9 December 2024	2.00	2.00
Interim dividend paid on 17 June 2025	2.00	2.00

Comments

Financial performance

The profit for the Group after providing for income tax amounted to \$6,730,441 (30 June 2024: \$6,964,488).

The directors consider Underlying Earnings Before Interest, Tax, Depreciation and Amortisation ('EBITDA') and Underlying EBIT to reflect the core earnings of the consolidated entity. Underlying EBITDA and underlying EBIT are financial measures which are not prescribed by Australian Accounting Standards ('AAS') and represent the profit or loss under AAS adjusted for non-cash and significant items. The following table summarises key reconciling items between statutory result and the underlying results for the current and previous year:

	Consolidated 2025 \$	2024 \$
Profit for the year	6,730,441	6,964,488
Depreciation and amortisation expense	510,858	391,537
Finance costs	27,835	24,754
Interest income	(417,874)	(195,738)
Income tax expense	3,855,592	2,994,690
EBITDA (excluding other income)	10,706,852	10,179,731

Financial position

The net assets increased from \$21,322,838 as at 30 June 2024 to \$28,085,315 as at 30 June 2025.

Share capital increased from \$6,852,670 as at 30 June 2024 to \$8,736,775 as at 30 June 2025 due to the issue of shares via employee incentives schemes and the exercise of performance rights.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>59.49</u>	<u>47.98</u>

The net tangible assets per ordinary security is calculated as follows:

	Consolidated 2025 \$	2024 \$
Net assets	28,085,315	21,322,838
Less: Right-of-use assets	(297,413)	(118,965)
Less: Intangibles	(28,130)	(18,848)
Add: Lease liabilities	304,489	123,856
Net tangible assets	<u>28,064,261</u>	<u>21,308,881</u>

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

	Amount per security Cents	Franked amount per security Cents
Final dividend paid on 9 December 2024	2.00	2.00
Interim dividend paid on 17 June 2025	2.00	2.00

Previous period

	Amount per security Cents	Franked amount per security Cents
Final dividend paid on 8 December 2023	1.00	1.00
Interim dividend paid on 17 June 2024	1.50	1.50

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

EZZ Life Science Holdings (USA) Inc., incorporated in USA.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unmodified opinion has been issued.

11. Attachments

Details of attachments (if any):

The Annual Report of EZZ Life Science Holdings Limited for the year ended 30 June 2025 is attached.

12. Signed

Signed _____ 

Qizhou (Mark) Qin
Executive Director
Sydney

Date: 29 August 2025